Day One Biopharma Elects New Directors, Adjusts Officer Compensation

Ticker: DAWN · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1845337

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

Day One Biopharma shakes up board with two new directors & revises exec pay.

AI Summary

Day One Biopharmaceuticals, Inc. announced on November 20, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. David J. Bearss and Ms. Jennifer L. Sim, to its Board of Directors. Additionally, the company entered into new employment agreements with certain officers, including an amended employment agreement with its Chief Medical Officer, Dr. Robert J. Smith.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can introduce uncertainty, but the specific details of the agreements will determine the actual risk.

Key Players & Entities

FAQ

Who were the new directors elected to Day One Biopharmaceuticals' Board?

Dr. David J. Bearss and Ms. Jennifer L. Sim were elected as new directors.

What is the date of this 8-K filing?

The filing date is November 20, 2024.

Did Day One Biopharmaceuticals enter into new employment agreements?

Yes, the company entered into new employment agreements with certain officers, including an amended employment agreement with its Chief Medical Officer.

What is the principal executive office address for Day One Biopharmaceuticals?

The principal executive office is located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California 94005.

What is the SIC code for Day One Biopharmaceuticals?

The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.

Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-11-20 16:33:55

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: November 20, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing